The Korea Food and Drug Administration (KFDA) announced on April 2 that Novartis Korea has halted sales of Zelmac (tegaserod), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, including angina and stroke, in those taking the drug.
The company will voluntarily remove Zelmac from the market.
The ischemic events came to li...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.